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should use any available tools for pharmacotherapy optimi-
zation—also genetic testing.
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Introduction
Voriconazole (VCZ) is a new-generation triazol antifungal 
agent. The drug is approved mainly for treatment of inva-
sive aspergillosis, candidiasis and infections caused by 
Scedosporium spp. and Fusarium spp. (SPC Vfend 2016). 
As it is more effective in the prevention of mold infections 
than fluconazole (FCZ) and itraconazole, VCZ is also used 
in prophylaxis of invasive fungal infections (IFI) among 
immunocompromised patients undergoing allogenic hemat-
opoietic stem cell transplantation (allo-HSCT) (Xu et  al. 
2013).
The drug is metabolized in the liver by CYP2C19, 
CYP3A4 and CYP2C9. Only mutations of the first isoen-
zyme have been reported to cause variability in voricona-
zole pharmacokinetics (Moriyama et al. 2015). This is why 
many scientists postulate the need for CYP2C19 genotyp-
ing for therapeutic drug monitoring of VCZ (Trubiano et al. 
2014).
The concomitant use of other medicines in the therapy 
of haematological malignancies leads to drug–drug inter-
actions. Especially the co-administration of voriconazole 
with phenytoin, fluconazole or cyclosporine A is reported 
to cause adverse effects due to changes in pharmacokinetic 
parameters (Purkins et  al. 2003; Damle et  al. 2011, SPC 
Sandimmun 2013).
In this paper, we present the case of more severe 
adverse drug reactions of VCZ in four patients with 
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genic hematopoietic stem cell transplantation, treated with 
voriconazole for prevention of fungal infections, to estab-
lish the impact of CYP2C19*2/*17 genotype on side effect 
occurrence.
Methods Genetic testing for CYP2C19 allele*2 and*17 
was performed using two PCR-RFLP methods established 
by Goldstein and Blaisdell, and Sim et al. All four patients 
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Results The patients suffered from gastrointestinal, der-
matological, neurological, hepatobiliary and renal adverse 
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use of VCZ. Other drugs potentially causing side effects 
were also taken into consideration. The presented compli-
cations were temporary and did not force dosage regimen 
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CYP2C19*2/*17 genotype after allo-HSCT and a concom-
itant drug–drug interaction analysis.
Case reports
Anamnesis
Four Caucasian patients, two males (aged 62 and 50) and 
two females (aged 61 and 63), with normal BMI were 
admitted to the Department and Clinic of Haematology, 
Blood Neoplasms, and Bone Marrow Transplantation for 
allogenic hematopoietic stem cell transplantation. The pri-
mary diseases were acute myeloid leukemia (AML) in two 
cases, myelodysplastic syndrome (MDS) and acute lymph-
oblastic leukemia (ALL). Three patients were treated with 
reduced-intensity conditioning (RIC) and one, suffering 
from ALL, with myeloablative conditioning (MAC). The 
treatment protocols are described below.
During RIC, mega-dose chemotherapy was performed 
using fludarabine I.V. on days −6 to −2, busulfan I.V. on 
days −5 to −2 inclusive and thymoglobulin I.V. on days −3 
to −1. For MAC, the regimen consisted of TBI (2 × 2.0 Gy/
day) and cyclophosphamide I.V. The patients received graft 
versus host disease (GVHD) prophylaxis combining cyclo-
sporine A (CyA) I.V. with methotrexate I.V. To avoid infec-
tions, a co-medication with trimethoprim (TMP) p.o., acy-
clovir (ACV) p.o., and fluconazole (FCZ) p.o. was started. 
The decontamination was performed using ciprofloxacin 
p.o. Three days before transplantation, ACV and FCZ 
administrations have been suspended and voriconazole I.V. 
with ganciclovir I.V. was introduced into therapy as IFI and 
viral infection prophylaxis. After allo-HSCT, omeprazole 
I.V. was included as ulcer prevention. The dose regiments 
were established according to the particular summaries of 
product characteristics (SPC).
Results
During VCZ pharmacotherapy, we observed adverse drug 
reactions (ADR) in frequency that was not noticed in other 
patients treated with the same protocols. One female dem-
onstrated nausea and dizziness. The second one suffered 
from vomiting, constipation, rush, exfoliative dermatitis, 
vertigo, ataxia and aphasia. Among male patients, elevation 
of GGT (gamma-glutamyl transpeptidase) and in one male 
nausea, vomiting, rush, erythema, pneumonia, nephritis as 
well as hematuria were observed.
We performed genetic testing for CYP2C19 allele *2 
and *17 determination, using two PCR-RFLP methods 
established by Goldstein and Blaisdell (1996) and Sim et al. 
(2006). All of the patients presented CYP2C19*2/*17 gen-
otype. To our knowledge there is no definite information 
in the literature on the impact of this diplotype on vori-
conazole pharmacokinetic properties, but there is evidence 
suggesting a poor metabolizer (PM) phenotype, causing 
adverse drug reactions due to higher VCZ serum levels 
(Cervinski et al. 2013).
On the other hand, there are drug–drug interactions 
between voriconazole, cyclosporine A and omeprazole. 
This type of co-medication also leads to increased VCZ 
concentrations and is, therefore, a factor influencing ADR 
occurrence (SPC Sandimmun 2013; Wood et al. 2003).
Treatment and progression
These presented complications were temporary and did 
not force dosage regimen adjustments or discontinuation 
of pharmacotherapy. After 2 months, the patients were dis-
charged from hospital.
Discussion
In the presented case report, adverse drug reactions of VCZ 
treatment occurred in patients with the CYP2C19*2/*17 
diplotype, suggesting rather a poor metabolizer phenotype. 
The frequency of this genotype in the Caucasian population 
and the influence on voriconazole pharmacokinetic prop-
erties are unknown yet. On one hand, Weiss et  al. (2009) 
reported that patients carrying this genetic variant demon-
strated the same pharmacokinetic properties of VCZ as the 
ones with CYP2C19*1/*17 genotype. On the other hand, 
Chung et al. (2015) stated in their article that patients with 
CYP2C19*2/*17 variant were rather IM (intermediate 
metabolizers), but they also underlined the need for further 
research on this topic.
In another study conducted by Harmsze et  al. (2012), 
the influence of CYP2C19 mutations on clopidogrel on-
treatment platelet reactivity was established. Clopidogrel is 
a prodrug that needs to be metabolized to its active form. 
In patients demonstrating the CYP2C19*2/*17 genotype, 
the on-treatment platelet reactivity was increased compared 
with wild type, *1/*17 and *17/*17 diplotypes suggesting 
that CYP2C19*2/*17 genetic variant is associated with 
lower enzymatic activity. This may lead to the hypothesis 
that in the presented cases, the genotype led to decreased 
enzymatic activity, higher VCZ serum levels and as a result 
to its adverse reactions.
Another factor that has to be taken into account is the 
concomitant use of omeprazole. The drug is a competitive 
inhibitor of CYP2C19 isoenzyme. Its influence on the 
pharmacokinetic properties of voriconazole was estab-
lished. Wood et  al. (2003) showed that the co-adminis-
tration of omeprazole leads to increased VCZ blood con-
centrations, what in case of our patients, considered to be 
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PM, could have led to a greater elevation of voriconazole 
serum levels, and as a consequence to noticeable side 
effects (Boyd et al. 2012).
Certainly, the presented adverse effects may occur 
due to other drugs used in the patients’ treatment. Apart 
from gastrointestinal disturbances, such as nausea, vomit-
ing and constipation, that are very frequent ADR during 
pharmacotherapy at all, hepatobiliary (GGT elevation), 
skin (exfoliative dermatitis, erythema), nervous sys-
tem (ataxia) and renal disorders (nephritis) are undesir-
able effects common during VCZ treatment (SPC Vfend 
2016).
Other observed ADR such as dizziness, vertigo, aphasia 
and pneumonia are more likely connected with methotrex-
ate and cyclosporine A administration (SPC Sandimmun 
2013, SPC Methotrexat-Ebewe 2016). This conclusion is 
based on the investigation of Mori et al. (2009) who dem-
onstrated that voriconazole inhibits P-gp (P-glycoprotein) 
and increases CyA blood concentrations leading to adverse 
drug reactions, as cyclosporine A has a narrow therapeu-
tic window, and the frequently noticed ADR during MTX 
treatment (SPC Methotrexat-Ebewe 2016).
Conclusion
By reporting these cases, we would like to emphasize that 
drug–drug interactions and side effects may occur even if 
an agent is used for prophylaxis only. The definite identi-
fication of the medication causing ADR during polyphar-
macotherapy, e.g., accompanying allogenic hematopoietic 
stem cell transplantation, is challenging. Therefore, any 
available tools for pharmacotherapy optimization should be 
used including genetic testing.
In the presented case, previous determination of 
CYP2C19 mutation may have helped to avoid, at least 
partially, undesirable effects connected with voriconazole 
administration.
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